If FRα is expressed mainly in cancer cells, rather than in healthy tissues, and higher expression levels correlate to more severe disease and more aggressive cancers, it would make sense to train our immune system to block this receptor after remission is achieved. The gene discussed is FOLR1; the disease is cancer.